BioPharma Dive1d
Editas, changing course again, looks to partner lead CRISPR therapy
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...
STAT1d
Editas tacks again, steering from lead sickle cell treatment to new one
Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...
Buy Rating for Editas Medicine: Promising In Vivo CRISPR Platform and Strategic Growth Potential Amid Speculative Investment
Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...
GlobalData on MSN19d
Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m
Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue stream ...
STAT1d
‘Switchable’ CAR-T startup raises $112 million
AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...
precisionmedicineonline16h
Editas Seeking Partner or Licensing Deal for Lead Sickle Cell, TDT Gene-Editing Treatment Candidate
The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.
Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript
Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...
Future Market Insights1d
CRISPR and Cas Gene Market Expected to Reach USD 32.9 Billion by 2033 New Heights with Projected Growth of 30.2% of CAGR
The global CRISPR and Cas Gene Market was valued at USD 1.8 billion in 2021. With an impressive projected growth rate of 30.2 ...